MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijgc.2026.104852

Медицинская библиотека · International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026

Longitudinal kinetics of human epididymis protein 4 in recurrent advanced ovarian carcinoma treated with platinum-based chemotherapy: mathematical modeling and prognostic implications.

Nardelli Petra, Leitner Katharina, Carrot Aurore, Irsara Julia, Jaritz Julia, Schult Julia, Triendl Paul, Schnaiter Simon, Corbaux Pauline, Freyer Gilles, Marth Christian, Fiegl Heidelinde, You Benoit, Colomban Olivier

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

Evidence on the clinical utility of baseline human epididymis protein 4 levels and their kinetics in recurrent ovarian cancer remains limited. This study evaluated longitudinal human epididymis protein 4 dynamics in real-world patients treated with platinum-based chemotherapy, aiming to determine the prognostic significance of human epididymis protein 4 kinetic parameters compared with CA125 response and established prognostic factors for progression-free and overall survival.

METHODS

This retrospective analysis included 220 patients with recurrent epithelial ovarian cancer treated with second-line platinum-based chemotherapy between 2000 and 2020. Four mathematical models were tested to describe human epididymis protein 4 kinetics, with model selection based on goodness of fit, visual predictive checks, and prognostic performance. The prognostic value of the most informative human epididymis protein 4 kinetic parameter (the modeled residual human epididymis protein 4 level), was assessed in univariable and multi-variable analyses.

RESULTS

Among the 93 assessable patients, no clear associations were observed between baseline human epididymis protein 4 levels and disease characteristics. Longitudinal human epididymis protein 4 kinetics differed from those of CA125 and showed an initial decline followed by a plateau at approximately 40 days. The best-fitting model was a mono-exponential decline incorporating the modeled residual human epididymis protein 4 parameter, which was subsequently evaluated as a prognostic factor. Baseline human epididymis protein 4 levels lacked prognostic significance for progression-free or overall survival. In contrast, a higher modeled residual human epididymis protein 4 level was significantly associated with shorter progression-free and overall survival in univariable analyses (residual human epididymis protein 4 ≥median vs <median; median progression-free survival: 7.2 vs 12.6 months, p =.002; median overall survival: 16.5 vs 34.9 months; p =.001) and in multi-variable models (overall survival: hazard ratio 2.65; 95% confidence interval 1.23 to 5.71, p =.012) alongside CA125 response.

CONCLUSIONS

In this study, we identified residual HE4 levels in patients treated with second-line platinum-based chemotherapy as an independent dynamic marker of overall survival, with higher levels indicating poorer outcomes and potential chemoresistance.

Для цитирования: Nardelli Petra, Leitner Katharina, Carrot Aurore, Irsara Julia, Jaritz Julia, Schult Julia, Triendl Paul, Schnaiter Simon, Corbaux Pauline, Freyer Gilles, Marth Christian, Fiegl Heidelinde, You Benoit, Colomban Olivier. Longitudinal kinetics of human epididymis protein 4 in recurrent advanced ovarian carcinoma treated with platinum-based chemotherapy: mathematical modeling and prognostic implications.. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2026. DOI: 10.1016/j.ijgc.2026.104852.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.